Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study.
Bai X, Lawless AR, Czapla JA, Gerstberger SC, Park BC, Jung S, Johnson R, Yamazaki N, Ogata D, Umeda Y, Li C, Guo J, Flaherty KT, Nakamura Y, Namikawa K, Long GV, Menzies AM, Johnson DB, Sullivan RJ, Boland GM, Si L.
Bai X, et al. Among authors: yamazaki n.
JAAD Int. 2024 Jan 19;15:105-114. doi: 10.1016/j.jdin.2023.11.014. eCollection 2024 Jun.
JAAD Int. 2024.
PMID: 38500872
Free PMC article.